TGFB1 and anemia: Regarding therapeutic approaches, recent data [78] have led to the approval of sotatercept, a TGF-β signaling inhibitor for PH, by the FDA; this agent was previously shown to improve anemia and ineffective erythropoiesis in thalassemic patients [79].